Anglo Asian Mining Share Discussion Threads

[riggerbeautz] 08/6/2020 08:48

AA. First breach attempt at 30p, let’s see if it can get some volume. Plenty urging it on.

Edit just seeing the first sell signs over 30p, bodes well

[wimbled] 08/6/2020 08:46

UOG flying too......target 9.8p

[mad foetus] 08/6/2020 08:38

IPF flying too share price 74 all broker targets 250+

[2sporrans] 08/6/2020 08:34

completed my 36163 post now.

[lefrene] 08/6/2020 08:30

GoodGrief, I feel the integrity of the Board here is such, that they won't dodge awkward questions.

[goodgrief] 08/6/2020 08:26

Re. trust, last Autumn Bill ducked out of questions re. talks with Azeri government citing Takeover Code. I hope they come clean at the AGM? But with the format of this year's AGM they get to pick and choose what questions to answer!

[riggerbeautz] 08/6/2020 08:18

Muted? Depends where you look SHI, AML, MARS all flying at the start

[fozzie] 08/6/2020 08:16

Seems to be a very muted opening across the board, I was expecting a stronger start given strong US on Friday and rising price of oil.

[jbravo2] 08/6/2020 08:07

Yes the HUM RNS is ok compared to their previous appalling deals.
The only bit I don’t like on their deal is the royalty AND paying extra for reserves. One or the other seems fair to me.
However overall I agree it’s ok. Shame I don’t trust their board otherwise I’d be buying.

[brasso3] 08/6/2020 08:05

HUM RNS is the kind of aggressive approach I hope to see from AAZ.

[digger18] 08/6/2020 08:02

2019 profit of 30m and current Mcap of 140m. ITM power (yes a green product with a likely good future) loss of 17.5m for the year with an Mcap of 1.7B!!
Incredible valuation based on losses.
I know where I prefer my money to be at the moment unless you are a lucky trader riding a crazy market.

[gold finger 1] 08/6/2020 07:59

Anyone interested should take a look at HUM and it RNS this morning.
Then tell me this is over priced.

[2sporrans] 08/6/2020 07:58

To be fair to Lurker/DD, he did put across at least one good arguement
to support his bearish contention last year; that was to do with the scale of
the costs that will accompany an expansion phase.
He reckoned than that investors here were underestimating them and maybe the risks too, though I'm a bit hazy on the latter without going back to check.
A perfectly valid concern.
For most of us, the challenge of an expansion, albeit one we won't see much of until after 2025, [driven by poroxy arc discovery/development in Gedabek CA or Ordubad] is one to look forward to.

Anyway, for now, what we need more clarity on is the resource situation wrt the known epithermal stratum: Both the existing mine extensions [JORC updates} and the resource in the 5 new mine prospects - none of which were known a year ago.

On the Hardman update, I'm hoping that it will be based upon informed insight into an improved situation with these resources/LOMs; hoping for something more than we've been given to date in the RNSs.
Beear in mind that the JORC updates for Ged. + Gadir have been held back because of lockdown strictures precluding site visits/assessments by independent geologists.
Also, don't underestimate that a lot of the development costs for both underground mines [Gadir down-dip and Ged. u/G - new] have been sunk over the past year.
The new tunnel, vent shaft, cross passages [used for fan drilling initially] will of course comprise a large% of the development for the new Ged. u/g mine - given it goes ahead.
Does SW's team have a pretty shrewd idea of what the resource is for this main pit u/g prospect by now? I expect so. Ditto for Gadir down dip extension to come.
They would have wished to report on this with inclusion of JORCed reserves for what has been added to those since summer 2018 - main pit and spring 2019 Gadir but have not been able to do due to lack of independent Geo input as above.

Further, we have not had any recent explor. update as such, so no recent details on what this has found for the 5 new mine prospects, nor again for the main pit/Gadir extensions.
We are surely all waiting for a Q1 update to be released soon.
The strategic update RNS gave a big nod towards what to expect with this and a JORC/LOMs report later in Q3 did it not?

[gold finger 1] 08/6/2020 07:49

I see the directors at CEY have received a nice big share bonus today.
Another massive plus here,that we don't have greedy directors,always feeding themselves shares at the cost of shareholders.

[wanobi] 08/6/2020 07:39

4D - a great post by realist on the 4D thread this weekend,,, I hope he/she doesn't mind, but I've copied it here for us newbies to refer to,,,, many thanx realist, great post, cheers Wan :-)

Gentlemen,

The discussion around funding is valid....but only up to a point.

The inexperienced amongst us should understand that investing in pharma companies (especially ones aiming to bring a whole new class of drug to the market) are much like early-phase technology companies: they often have high cash burn rates against a backdrop of limited cash generation. They are, quite understandably, heavy on R&D.

This is nearly always a given and it's one of the main reasons they are publicly listed in the first instance. Funding and the ongoing need for cash are amongst the first things to be aware of when staking a claim to part of that business, with your own money. Be sure to understand that they may well need more.

The good news here is that 4D now has years behind it where a good deal of work has already been done. Most importantly, in the immediate future it also has a number of potentially highly value accretive events lined up. Or, as the management phrase it 'shots on goal'.

Any one of these has the potential to be transformative for the company.

I believe the reason why the management have recently invested so heavily is because they anticipate some of these value accretive events to come good and so propel the valuation significantly north. That, of course, does not mean the company will no longer require cash. In all probability it probably will, but I suspect they think future fundraisings will be done at higher prices and will therefore be less dilutive.

4D has very few shares in issue and whilst we are currently being frustrated by a seller dribbling stock into the market, this will, at some point, cease. The share price should then climb well on even modest buying, without news, let alone with it.

Always look at the valuation first, before purchasing. In my eyes, it does not look at all toppy. The IP, the patents, the manufacturing facility, knowledge base and the fairly advanced trials are compelling and each and all have significant value. I believe if any competing firm wanted what 4D have, they would have to pay well in advance of the current market cap.....and that's without completion of any of the existing trials. This is not an expensive company, at least not in my eyes.

A good proportion of the shares are now out of circulation and will be tightly held. When the stock dribble has ended I anticipate 4D to trend positively.....with the added bonus of a goal along the way. If that happens expect predatory interest if the company is still sitting on a low valuation. The company will in all probability be bought out before it begins generating huge sums of cash, or it will license, grow and either merge or be taken out....but that is for the future.

In my opinion, Mr. Peyton is clearly a 'money-man' more than a scientist.......and looks like a deal-maker. That's not a bad thing at all. And the recent ramp-up we've seen in engaging with the wider market is a good and encouraging sign. It suggests he is keen to manage not only the business and the science but also the valuation; he is, like us, probably acutely aware of the money he has recently spent. As I said before, this correlation may seem obvious, but, ironically, they do not always go hand in glove. Over the years, I've seen many CEO's ignore the market and hope that 'the valuation will look after itself'. A good CEO will of course orchestrate the company, hire the right people and drive value accretive events.....but one who also has skin in the game and who watches his companies valuation too, is to be welcomed.

First off is to see how our shots on goal go this year. Hopefully 4D will break the net. If (IF) that happens there is no reason why a future fundraise need be a 'painful' or 'negative' event, for it will happen for all the right reasons, at the right price and, we hope, to the right people. The more success the company proves-up, the more options it will have.......and perhaps including new broker services, should the company deem that it's existing one has hitherto not performed adequately. In the past I have brought a few brokers to book for their inadequacy and in one instance encouraged their replacement to the ultimate benefit of the company.

Sorry for the egg suck to those who are experienced, but for those who are not, I hope the above brings a certain perspective.

[wanobi] 08/6/2020 07:26

Brent at 42.90 :-)
Gold at 1690 :-)

Cheers
Wan :-)

[pogue] 08/6/2020 07:21

Positive EVG RNS may move the price today...


Paper published on SFX-01 in ER positive breast cancer
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the publication of a scientific paper entitled " Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer". SFX-01 is the Company's synthetic formulation of stabilised sulforaphane (SFN).
The paper, in the prestigious journal Oncogene, is co-authored by Bruno Simoes, Research Fellow at the Division of Molecular & Clinical Cancer Sciences, The University of Manchester and Sacha Howell, Honorary Consultant in Medical Oncology at the Christie Hospital. The paper describes a body of work carried out in a collaboration between Evgen and the University of Manchester, over a number of years, on the potential use SFX-01 to combat endocrine resistance in ER-positive breast cancer.
The paper reports that SFX--01, used in combination with endocrine therapies, prevents breast cancer stem-like cell (CSC) enrichment in patient samples and patient-derived xenograft tumours. Thus SFX-01 reduces the formation of stem-like cells (thought to be the clones that survive once tumours are treated with therapies such as endocrine therapies, and which cause metastases). SFX-01 also blocks STAT-3, itself implicated in resistance to endocrine therapies. SFX-01 therefore has the potential to overcome such resistance and improve clinical outcomes.
The paper can be viewed at: and on the Evgen website.
Barry Clare, Executive Chairman of Evgen, commented:
"This paper clearly elucidates the potential of SFX-01 in the treatment of ER+ metastatic breast cancer and its potential as a STAT3 inhibitor. We look forward to building on this work, and on the data from our successful phase II trial in metastatic breast cancer, in the next trial."

[brasso3] 08/6/2020 07:18

Very interesting RNS at HUM

These are the kind of deals that I hoped AAZ would be looking for.

[wanobi] 08/6/2020 07:18

Good morning all, good luck and Good health to you all this week :-) Cheers Wan :-)

[podgyted] 08/6/2020 00:17

Dollar weakness becoming a problem here.

What is the Hardman report going to add?

[swallowsflysouth] 07/6/2020 22:47

Leopold, i'm a holder of TSG, massive potential, checkout their last drilling results if you have not already done so. My main concern is where they are. However most pm mining companies contain some risk on the country that they are in. You have to make your own judgement on that one.

[riggerbeautz] 07/6/2020 21:51

Mj, my only ever doubt and why I traded it, rather than stick around, was the ownership intentions given previous companies from that way on. That they communicate so little added to doubts; I know you have referenced WCC but that was a rare swan in waters full of ugly ducklings.

Will pay your thread a visit and look again, maybe hold my nose for the ride.

[baddeal] 07/6/2020 21:51

DD thanks for all the great insight you have shared! I'm sure I read somewhere else to buy low and sell high but thanks for reminding me.I've been investing (not trading) in mkts for 30 years and never worry too much whether I miss an up spike or down trough. Truth is you can count on one hand people who bought at the lows and sell at the highs.Anyway given your extreme skill in this game I'd love to hear of any of your great recommendations. Ps that is ones for the future not ones with hindsight.....

[doc_oj] 07/6/2020 21:30

spot on friendzarin - don't know why or how but his/her appearance and persistence does strongly suggest the share price should be doing well in the near term!